- 2026-12-05
-
Response-independent overall survival benefit in the phase 3 ROSELLA Trial (APGOT-Ov10) of relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer
11:27-11:35
Hall B
Best Oral
Speaker
- 2026-12-06
-
Pembrolizumab vs placebo + paclitaxel ± bevacizumab for platinum-resistant recurrent ovarian cancer: post hoc analysis in the East Asia subgroup of the ENGOT-ov65/KEYNOTE-B96 study
07:25-07:32
Room 502
Mini Oral
Speaker
-
Panel Discussion
09:05-09:23
Room 503
MTB
MTB 2: Cervical Cancer with KRAS Mutations
Panelist
-
10:55-12:15
Hall A
Best Oral
Best Oral Session 3: Late-Breaking Abstracts
Moderator
-
Commentary on LBA03 and LBA04
11:55-12:05
Hall A
Best Oral
Best Oral Session 3: Late-Breaking Abstracts
Speaker


